Repligen (RGEN) Stock Forecast, Price Target & Predictions
RGEN Stock Forecast
Repligen stock forecast is as follows: an average price target of $201.67 (represents a 19.05% upside from RGEN’s last price of $169.40) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
RGEN Price Target
The average price target for Repligen (RGEN) is $201.67 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $220.00 to $185.00. This represents a potential 19.05% upside from RGEN's last price of $169.40.
RGEN Analyst Ratings
According to 10 Wall Street analysts, Repligen's rating consensus is 'Buy'. The analyst rating breakdown for RGEN stock is 0 'Strong Buy' (0.00%), 8 'Buy' (80.00%), 1 'Hold' (10.00%), 1 'Sell' (10.00%), and 0 'Strong Sell' (0.00%).
Repligen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | Paul Knight | KeyBanc | $220.00 | $148.59 | 48.06% | 29.87% |
| Jul 31, 2024 | Rachel Vatnsdal | J.P. Morgan | $200.00 | $167.35 | 19.51% | 18.06% |
| Jul 31, 2024 | Elizabeth Garcia | UBS | $185.00 | $167.35 | 10.55% | 9.21% |
| Jun 26, 2024 | Justin Bowers | Deutsche Bank | $155.00 | $127.00 | 22.05% | -8.50% |
| Jun 21, 2024 | Daniel Arias | Stifel Nicolaus | $207.00 | $123.16 | 68.07% | 22.20% |
| Jan 06, 2023 | Leerink Partners | $200.00 | $153.32 | 30.45% | 18.06% | |
| Dec 14, 2022 | Deutsche Bank | $180.00 | $177.99 | 1.13% | 6.26% | |
| Dec 07, 2022 | RBC Capital | $190.00 | $169.13 | 12.34% | 12.16% | |
| Apr 28, 2022 | Leerink Partners | $220.00 | $157.51 | 39.67% | 29.87% |
The latest Repligen stock forecast, released on Nov 12, 2024 by Paul Knight from KeyBanc, set a price target of $220.00, which represents a 48.06% increase from the stock price at the time of the forecast ($148.59), and a 29.87% increase from RGEN last price ($169.40).
Repligen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 5 |
| Avg Price Target | - | $220.00 | $193.40 |
| Last Closing Price | $169.40 | $169.40 | $169.40 |
| Upside/Downside | -100.00% | 29.87% | 14.17% |
In the current month, the average price target of Repligen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Repligen's last price of $169.40. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 12, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Sep 26, 2024 | UBS | Underperform | Underperform | Hold |
| Sep 26, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 27, 2024 | Wells Fargo | Overweight | Initialise | |
| Jul 31, 2024 | UBS | Buy | Buy | Hold |
| Jun 26, 2024 | BMO Capital | Outperform | Upgrade | |
| Jun 26, 2024 | Deutsche Bank | Hold | Buy | Upgrade |
| Jun 18, 2024 | Guggenheim | Neutral | Initialise | |
| Feb 21, 2024 | William Blair | Outperform | Outperform | Hold |
| Oct 31, 2023 | William Blair | Outperform | Outperform | Hold |
| Jul 06, 2023 | Piper Sandler | Underweight | Downgrade | |
| Jul 06, 2023 | Raymond James | Outperform | Initialise | |
| Jul 06, 2023 | UBS | Neutral | Downgrade | |
| Jul 06, 2023 | RBC Capital | Sector Perform | Outperform | Upgrade |
| Jan 06, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| Dec 14, 2022 | Deutsche Bank | Hold | Initialise | |
| Dec 07, 2022 | RBC Capital | Sector Perform | Initialise | |
| Apr 28, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Feb 18, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Repligen's last stock rating was published by KeyBanc on Nov 12, 2024. The company gave RGEN a "Overweight" rating, the same as its previous rate.
Repligen Financial Forecast
Repligen Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $141.19M | $159.17M | $182.66M | $186.76M | $200.74M | $207.63M | $206.40M | $186.52M | $178.22M | $162.96M | $142.84M | $108.65M | $94.06M | $87.46M | $76.09M | $69.47M | $69.44M |
| Avg Forecast | $210.06M | $199.76M | $195.88M | $186.66M | $186.67M | $171.84M | $172.66M | $164.05M | $167.64M | $153.02M | $154.11M | $150.06M | $155.38M | $140.69M | $165.93M | $181.42M | $184.55M | $191.50M | $189.06M | $185.48M | $179.27M | $163.91M | $144.24M | $117.02M | $93.94M | $86.45M | $78.38M | $71.64M | $68.37M | $66.10M |
| High Forecast | $215.99M | $205.41M | $201.42M | $191.93M | $191.94M | $176.69M | $177.54M | $167.18M | $170.12M | $153.25M | $154.11M | $150.06M | $157.82M | $149.04M | $170.62M | $186.55M | $189.94M | $191.50M | $189.06M | $185.48M | $179.27M | $163.91M | $144.24M | $117.02M | $93.94M | $86.45M | $78.38M | $71.64M | $68.37M | $66.10M |
| Low Forecast | $201.90M | $192.01M | $188.28M | $179.41M | $179.42M | $165.16M | $165.96M | $158.29M | $166.02M | $152.79M | $154.11M | $150.06M | $151.54M | $134.19M | $159.49M | $174.37M | $177.56M | $191.50M | $189.06M | $185.48M | $179.27M | $163.91M | $144.24M | $117.02M | $93.94M | $86.45M | $78.38M | $71.64M | $68.37M | $66.10M |
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 12 | 6 | 3 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.96% | 1.01% | 1.01% | 1.05% | 1.10% | 1.11% | 1.04% | 1.09% | 1.13% | 1.22% | 1.16% | 1.09% | 1.12% | 1.06% | 1.02% | 1.05% |
Repligen's average Quarter revenue forecast for Dec 23 based on 7 analysts is $155.38M, with a low forecast of $151.54M, and a high forecast of $157.82M. RGEN's average Quarter revenue forecast represents a 10.05% increase compared to the company's last Quarter revenue of $141.19M (Sep 23).
Repligen EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 12 | 6 | 3 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.81M | $19.40M | $32.11M | $32.12M | $55.98M | $64.53M | $68.57M | $49.11M | $54.46M | $56.48M | $44.66M | $25.36M | $27.51M | $25.50M | $20.04M | $13.39M | $10.27M |
| Avg Forecast | $55.43M | $52.71M | $51.69M | $49.25M | $49.25M | $45.34M | $45.56M | $43.29M | $44.23M | $40.38M | $40.66M | $71.41M | $41.00M | $37.12M | $43.78M | $64.92M | $40.72M | $38.87M | $38.37M | $51.32M | $36.39M | $33.27M | $29.28M | $18.71M | $19.07M | $17.55M | $15.91M | $10.50M | $13.88M | $13.42M |
| High Forecast | $56.99M | $54.20M | $53.15M | $50.64M | $50.65M | $46.62M | $46.85M | $44.11M | $44.89M | $40.44M | $40.66M | $85.69M | $41.64M | $39.33M | $45.02M | $77.90M | $48.87M | $38.87M | $38.37M | $61.58M | $36.39M | $33.27M | $29.28M | $22.46M | $19.07M | $17.55M | $15.91M | $12.60M | $13.88M | $13.42M |
| Low Forecast | $53.27M | $50.66M | $49.68M | $47.34M | $47.34M | $43.58M | $43.79M | $41.77M | $43.81M | $40.31M | $40.66M | $57.13M | $39.99M | $35.41M | $42.08M | $51.93M | $32.58M | $38.87M | $38.37M | $41.06M | $36.39M | $33.27M | $29.28M | $14.97M | $19.07M | $17.55M | $15.91M | $8.40M | $13.88M | $13.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.13% | 0.44% | 0.49% | 0.79% | 1.44% | 1.68% | 1.34% | 1.35% | 1.64% | 1.93% | 2.39% | 1.33% | 1.57% | 1.60% | 1.91% | 0.96% | 0.77% |
7 analysts predict RGEN's average Quarter EBITDA for Dec 23 to be $41.00M, with a high of $41.64M and a low of $39.99M. This is 752.73% upper than Repligen's previous annual EBITDA (Sep 23) of $4.81M.
Repligen Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 12 | 6 | 3 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $18.17M | $20.06M | $28.83M | $48.73M | $40.41M | $49.86M | $46.96M | $29.11M | $33.50M | $36.23M | $29.45M | $19.70M | $14.55M | $15.86M | $9.81M | $3.60M | $1.66M |
| Avg Forecast | $33.44M | $30.07M | $29.87M | $27.36M | $28.99M | $24.34M | $24.55M | $20.95M | $23.50M | $19.10M | $18.57M | $47.20M | $18.55M | $9.39M | $27.05M | $42.91M | $24.14M | $38.37M | $40.28M | $33.92M | $36.61M | $35.94M | $29.56M | $12.34M | $17.28M | $15.59M | $15.67M | $5.14M | $10.41M | $10.86M |
| High Forecast | $34.67M | $31.18M | $30.97M | $28.37M | $30.06M | $25.23M | $25.45M | $24.34M | $25.80M | $19.11M | $18.57M | $56.64M | $19.67M | $17.60M | $28.05M | $51.49M | $28.97M | $38.37M | $40.28M | $40.70M | $36.61M | $35.94M | $29.56M | $14.81M | $17.28M | $15.59M | $15.67M | $6.17M | $10.41M | $10.86M |
| Low Forecast | $31.75M | $28.55M | $28.36M | $25.98M | $27.53M | $23.11M | $23.31M | $15.28M | $20.07M | $19.09M | $18.56M | $37.76M | $17.43M | $5.28M | $25.69M | $34.33M | $19.31M | $38.37M | $40.28M | $27.13M | $36.61M | $35.94M | $29.56M | $9.87M | $17.28M | $15.59M | $15.67M | $4.11M | $10.41M | $10.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.94% | 0.74% | 0.67% | 2.02% | 1.05% | 1.24% | 1.38% | 0.80% | 0.93% | 1.23% | 2.39% | 1.14% | 0.93% | 1.01% | 1.91% | 0.35% | 0.15% |
Repligen's average Quarter net income forecast for Dec 23 is $18.55M, with a range of $17.43M to $19.67M. RGEN's average Quarter net income forecast represents a 2.08% increase compared to the company's last Quarter net income of $18.17M (Sep 23).
Repligen SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 12 | 6 | 3 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $55.47M | $48.97M | $56.17M | $53.24M | $53.64M | $54.65M | $54.30M | $52.06M | $48.37M | $44.34M | $39.09M | $36.34M | $29.05M | $26.73M | $27.50M | $28.29M | $24.63M |
| Avg Forecast | $65.83M | $62.60M | $61.38M | $58.49M | $58.50M | $53.85M | $54.11M | $51.41M | $52.53M | $47.95M | $48.29M | $54.57M | $48.69M | $44.09M | $52.00M | $49.61M | $43.17M | $57.57M | $56.84M | $39.22M | $53.89M | $49.27M | $43.36M | $16.38M | $28.24M | $25.99M | $23.56M | $14.40M | $20.55M | $19.87M |
| High Forecast | $67.69M | $64.37M | $63.12M | $60.15M | $60.15M | $55.37M | $55.64M | $52.39M | $53.31M | $48.02M | $48.30M | $65.48M | $49.46M | $46.70M | $53.47M | $59.53M | $51.80M | $57.57M | $56.84M | $47.06M | $53.89M | $49.27M | $43.36M | $19.66M | $28.24M | $25.99M | $23.56M | $17.29M | $20.55M | $19.87M |
| Low Forecast | $63.27M | $60.17M | $59.00M | $56.22M | $56.22M | $51.76M | $52.01M | $49.60M | $52.03M | $47.88M | $48.29M | $43.66M | $47.49M | $42.05M | $49.98M | $39.69M | $34.53M | $57.57M | $56.84M | $31.37M | $53.89M | $49.27M | $43.36M | $13.11M | $28.24M | $25.99M | $23.56M | $11.52M | $20.55M | $19.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.26% | 0.94% | 1.13% | 1.23% | 0.93% | 0.96% | 1.38% | 0.97% | 0.98% | 1.02% | 2.39% | 1.29% | 1.12% | 1.13% | 1.91% | 1.38% | 1.24% |
Repligen's average Quarter SG&A projection for Dec 23 is $48.69M, based on 7 Wall Street analysts, with a range of $47.49M to $49.46M. The forecast indicates a -12.21% fall compared to RGEN last annual SG&A of $55.47M (Sep 23).
Repligen EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 10 | 12 | 6 | 3 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.33 | $0.36 | $0.52 | $0.88 | $0.73 | $0.90 | $0.85 | $0.53 | $0.61 | $0.66 | $0.54 | $0.37 | $0.28 | $0.30 | $0.19 | $0.07 | $0.03 |
| Avg Forecast | $0.59 | $0.53 | $0.52 | $0.48 | $0.51 | $0.43 | $0.43 | $0.37 | $0.41 | $0.34 | $0.33 | $0.30 | $0.33 | $0.16 | $0.48 | $0.59 | $0.58 | $0.68 | $0.71 | $0.72 | $0.65 | $0.64 | $0.52 | $0.42 | $0.31 | $0.28 | $0.28 | $0.22 | $0.18 | $0.19 |
| High Forecast | $0.61 | $0.55 | $0.54 | $0.50 | $0.53 | $0.44 | $0.45 | $0.43 | $0.45 | $0.34 | $0.33 | $0.30 | $0.35 | $0.31 | $0.49 | $0.61 | $0.60 | $0.68 | $0.71 | $0.72 | $0.65 | $0.64 | $0.52 | $0.42 | $0.31 | $0.28 | $0.28 | $0.22 | $0.18 | $0.19 |
| Low Forecast | $0.56 | $0.50 | $0.50 | $0.46 | $0.48 | $0.41 | $0.41 | $0.27 | $0.35 | $0.34 | $0.33 | $0.30 | $0.31 | $0.09 | $0.45 | $0.56 | $0.55 | $0.68 | $0.71 | $0.72 | $0.65 | $0.64 | $0.52 | $0.42 | $0.31 | $0.28 | $0.28 | $0.22 | $0.18 | $0.19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00% | 0.76% | 0.88% | 1.53% | 1.07% | 1.26% | 1.18% | 0.82% | 0.96% | 1.26% | 1.28% | 1.21% | 1.01% | 1.08% | 0.86% | 0.38% | 0.16% |
According to 7 Wall Street analysts, Repligen's projected average Quarter EPS for Dec 23 is $0.33, with a low estimate of $0.31 and a high estimate of $0.35. This represents a -1.28% decrease compared to RGEN previous annual EPS of $0.33 (Sep 23).
Repligen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $98.00 | $250.86 | 155.98% | Buy |
| HAE | Haemonetics | $68.29 | $107.00 | 56.68% | Buy |
| TFX | Teleflex | $180.58 | $257.67 | 42.69% | Buy |
| ATR | AptarGroup | $157.11 | $200.00 | 27.30% | Buy |
| HOLX | Hologic | $71.41 | $87.33 | 22.29% | Buy |
| RGEN | Repligen | $169.40 | $201.67 | 19.05% | Buy |
| WST | West Pharmaceutical Services | $339.57 | $393.00 | 15.73% | Buy |
| ICUI | ICU Medical | $168.30 | $190.50 | 13.19% | Buy |
| BDX | Becton, Dickinson and | $246.90 | $278.75 | 12.90% | Buy |
| ANGO | AngioDynamics | $12.46 | $13.00 | 4.33% | Buy |
| MMSI | Merit Medical Systems | $108.48 | $105.60 | -2.65% | Buy |
| ISRG | Intuitive Surgical | $572.71 | $556.50 | -2.83% | Buy |
| NVST | Envista | $21.37 | $20.29 | -5.05% | Hold |
| RMD | ResMed | $252.86 | $233.50 | -7.66% | Hold |